Glaucoma Therapeutics Market Bwc19434

Glaucoma Therapeutics Market, By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26

  • Published Date: March 2020
  • Report ID: BWC19434
  • Available Format: PDF
  • Page: 180

Report Overview

Global Glaucoma Therapeutics Market Forecast and Trends

The global Glaucoma Therapeutics market has reached 6272.89 million in 2019 and estimated to reach USD 7658.98 million in 2026 and anticipated to grow by CAGR of 2.96% during the forecast period 2020-2026. Increasing physician's preference to laser surgery for glaucoma care would accelerate the growth of the demand for glaucoma therapy over the forecast period. Improved diagnostic tools in the ophthalmic industry and a growing pool of geriatric population worldwide contribute considerably to the growth of the glaucoma therapeutics market. Furthermore, the late-stage pipeline therapy provides promise for glaucoma care, while the launch of novel therapeutic approaches by key players on the global market is expected to fuel the growth of the glaucoma therapy industry over the 2020-2026 forecast period. The recent development in intraocular imaging technology is expected to offer lucrative market prospects in the clinical sector for the glaucoma therapeutics market in upcoming years.

Global Glaucoma Therapeutics Market: Overview

Glaucoma is the eye disease that damages the optics of the patient's eye nerve. The extra fluid forming up in the front of the eye causes damage to the optics of the eye nerve. Glaucoma is a two-type, primary open-angle glaucoma & angle-closure glaucoma, often referred to as narrow-angle glaucoma. The most common type of glaucoma is Open-Angle glaucoma. Primary glaucoma eventually develops when the eye does not absorb the fluids. This results in pressure building on the optics of eye nerves. Open glaucoma does not induce any alteration in the vision of the eye, and it is also painless. Closed-angle glaucoma occurs very close to the drainage angle, which results in a blockage of the eyesight drainage angle. That is a form of glaucoma that is very acute.  This type of glaucoma can affect the patient's vision and can lead to severe eye and headache pain.  Glaucoma is generally treated with eye drops, pills, conventional surgery, laser surgery, and sometimes these approaches combined. Regular drug consumption, as prescribed by the doctor, is essential for proper glaucoma treatment.  Glaucoma drugs have much fewer chances of effects, which have increased its adoption on the global market.

Growth Drivers

The increasing prevalence rate of glaucoma

The shift in people's lifestyle has led to an increase in glaucoma prevalence globally. Increasing glaucoma prevalence is the primary factor driving the development of the global demand for glaucoma therapy. Glaucoma is more common in people older than 60 years. The rising geriatric population believed that the world is also responsible for the robust growth of the demand for glaucoma therapy over the forecast period.

Improving Diagnostic techniques coupled with rising government support

Improving diagnostic techniques, developing new drug delivery systems, and introducing new drug combinations combined with increasing glaucoma patients are key factors driving the growth of the therapeutic market for glaucoma worldwide. Increased government support and healthcare companies ' initiatives in raising awareness about glaucoma treatment also support market growth.


High Cost & low availability of skilled professionals for laser surgery

Lack of availability of specialized laser surgery professionals in developing economies will also hamper the growth of the market for glaucoma therapy. Besides, high costs associated with glaucoma medication and treatment are a key factor that can hinder the rate of growth in the global glaucoma therapy market.

Global Glaucoma Therapeutics Market: Disease Indication

The global market for glaucoma treatment is classified in terms of disease classification into open-angle glaucoma, angle-closure glaucoma, and others (congenital glaucoma, secondary glaucoma, etc.). Open-angle glaucoma is the highly prevalent sign of disease among all forms of glaucoma and is expected to lead the industry in the coming years. Besides, increasing demand by pharmaceutical companies for prescription drugs and strategic alliances for the need for new medicines driving the demand for Open-Angle glaucoma market in the category with a lucrative growth rate for the 2020-2026 forecast.

Global Glaucoma Therapeutics Market: Drug Class

The glaucoma therapy market segmented into analogs of prostaglandin, beta-blockers, alpha agonists, and carbonic anhydrase inhibitors based on drug class. The highest market share in the Prostaglandin Analogues category by 2026. Prostaglandins have changed the face of the care scenario for glaucoma and are used as first-line glaucoma therapy. The prostaglandin analogs segment represented a significant market share in 2019 and is expected to remain dominant over the 2020-2026 forecast period. Attributable to their efficacy as opposed to other treatments in reducing the 10P and fewer side effects. The category of prostaglandin analogs is further categorized into latanoprost, bimatoprost, travoprost, and others, where latanoprost captured the highest revenue share due to its substantial penetration in highly prevalent and emerging economies.

Global Glaucoma Therapeutics Market: Regional Insights

Global Glaucoma Therapeutics market segregated into five regions, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the glaucoma therapy segment due to the large healthcare system. Europe & Asia-Pacific, led by North America, will contribute significant growth in the global glaucoma market in the coming years. The favorable reimbursement scenario is responsible for the high growth of the glaucoma therapy market in Western Europe. Asia-Pacific area has also shown significant growth in the demand for glaucoma therapy due to the increase of the geriatric population. In the Asia-Pacific region over the forecast period, China and India are predicted to be the leading market for glaucoma therapy. Latin America and the Middle East and Africa are the least-profitable markets for glaucoma therapy due to less patient awareness of glaucoma.

Glaucoma Therapeutics: Competitive Landscape

The major market players in Glaucoma Therapeutics are Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries, Aerie Pharmaceutical, Pfizer Inc., Inotek Pharmaceuticals, Akorn Inc., Santen, and Other Prominent Players.

The objective of the Study:

To analyze and forecast the global market size of the Glaucoma Therapeutics.

Analyzing careful market segmentation and estimating value-based market size through region-based segmentation.

The global GlaucomaTherapeutics is divided into five regions: North America, Europe,

Asia-Pacific, Middle East, South America, and their leading countries.

To outline, categorize, and forecast the global AI in the agricultural market based on Disease Indication, Drug Class, and Distribution Channel with the region.

To examine competitive developments in the global Glaucoma market, such as technological advancement, services, and regulatory framework.

To emphasize the impact study of market dynamics variables such as users, constraints, opportunities, and challenges.

Profiling key players strategically and analyzing their market shares comprehensively, together with detailing the competitive environment for market leaders.

Scope of the Report:



Years Considered

Historical data – 2016-2019

Base Year – 2019

Forecast – 2020 – 2026

Facts Covered

Revenue in USD Million/Billion

Market Coverage

U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia

Product/Service Segmentation

By Disease Indication, Drug Class, and Distribution Channel

Key Players

Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries, Aerie Pharmaceutical, Pfizer Inc., Inotek Pharmaceuticals, Akorn Inc., Santen, and Other Prominent Players

By Disease Indication

·         Open-Angle Glaucoma

·         Angle Closure Glaucoma

·         Others

By Drug Class

·         Beta-Blockers

·         Prostaglandin Analogues

o    Latanoprost

o    Bimatoprost

o    Travoprost

o    Others

·         Alpha Adrenergic Agonists

·         Carbonic Anhydrase Inhibitors

·         Combination Drugs

·         Others

By Distribution Channel

·         Hospital Pharmacy

·         Retail Pharmacy

·         Online Pharmacy

By Region: 

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East & Africa

Business Questions Answer by the Report

How will the market drivers, restraints, and opportunities affect the market dynamics?

What will be the market size in terms of value and volume and market statistics with a detailed classification?

Which segment dominates the market or region, and one will be the fastest-growing, and why?

A comprehensive survey of the competitive landscape and the market participant players

Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority, and that’s why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:

Additional Company Information

With five additional company detail analysis

Additional country analysis

Detailed segment analysis